Liver Fibrosis

Fazirsiran effectively reduced the production and accumulation of a protein that causes alpha-1 antitrypsin deficiency and subsequent liver fibrosis in a small subset of patients, according to data in The New England Journal of Medicine.

A noninvasive liquid biopsy test diagnosed the presence and severity of nonalcoholic steatohepatitis and liver fibrosis more reliably than liver biopsy, according to research published in Gut.

LONDON — Elevated noninvasive markers of liver fibrosis correlated with an increased risk for cardiovascular events, end-stage renal disease and worse survival in patients with chronic kidney disease and nonalcoholic fatty liver disease.

Among patients with type 2 diabetes and normal thyroid function, thyroid hormone levels were linked to nonalcoholic fatty liver disease, suggesting assessment of these hormones might be beneficial for disease prevention and treatment.

SAN DIEGO — Higher sex hormone-binding globulin levels may predict liver fibrosis for men with nonalcoholic fatty liver disease, according to a presenter at the AACE Annual Scientific and Clinical Conference.

Weight loss induced by FDA-approved endoscopic bariatric and metabolic therapies improved several features of nonalcoholic fatty liver disease, with significant improvement in liver fibrosis, according to research.

Vibration-controlled transient elastography and fibrosis-4 index are effective alternatives to liver biopsy when evaluating risk for liver-related events in patients with nonalcoholic fatty liver disease, according to study results.

Using clinical bloodwork like FIB-4 and elastography technology in combination, Researchers at the International Liver congress proposed they could better identify patients with advanced fibrosis using clinical bloodwork like FIB-4 and elastography technology in combination.

Researchers said they launched the first study of its kind to assess the correlation between macronutrients and CVD. They concluded that replacing animal protein with plant protein at dinner could lower CVD risk by as much as 10%.

An oral hydrogel capsule for treatment of obesity may reduce liver fibrosis risk, according to an exploratory analysis of the GLOW study presented at the American Association of Clinical Endocrinology annual meeting.